Magrolimab Development Continues for the Treatment of AML and MDS - Targeted Oncology

Retrieved on: 2022-10-04 22:09:36

Tags for this article:

Click the tags to see associated articles and topics

Magrolimab Development Continues for the Treatment of AML and MDS - Targeted Oncology. View article details on hiswai:

Excerpt

“[Magrolimab] is a CD47 monoclonal antibody that has been combined with ... There are 4 different CD47 antibodies in clinic for AML and MDS.

Article found on: www.targetedonc.com